Skip to main content Deutsch

Grusch Lab

Michael Grusch, Assoc. Prof. Priv.-Doz. Mag. Dr.

Research Focus

We are interested in the regulation of cancer cell growth, migration, invasion and drug response by growth factors and related molecules. We aim to understand how growth factor signals contribute to malignancy and translate this knowledge into strategies for therapeutic interventions.

Within this area our main focus is on the role of fibroblast growth factors (FGF), epidermal growth factor (EGF), activins and Y-box binding protein 1 (YB-1) in pleural mesothelioma and lung cancer.

Selected Publications

EGF Induces Migration Independent of EMT or Invasion in A549 Lung Adenocarcinoma Cells
Schelch K, Vogel L, Schneller A, Brankovic J, Mohr T, Mayer RL, Slany A, Gerner C, Grusch M.
Front Cell Dev Biol. 2021 Mar 12;9:634371. doi: 10.3389/fcell.2021.634371. eCollection 2021.
PMID: 33777943 Free PMC article.

Activin A: an emerging target for improving cancer treatment?
Ries A, Schelch K, Falch D, Pany L, Hoda MA, Grusch M.
Expert Opin Ther Targets. 2020 Oct;24(10):985-996. doi: 10.1080/14728222.2020.1799350. Epub 2020 Aug 6. PMID: 32700590 Review.

Expression of FGFR1-4 in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity
Vlacic G, Hoda MA, Klikovits T, Sinn K, Gschwandtner E, Mohorcic K, Schelch K, Pirker C, Peter-Vörösmarty B, Brankovic J, Dome B, Laszlo V, Cufer T, Rozman A, Klepetko W, Grasl-Kraupp B, Hegedus B, Berger W, Kern I, Grusch M.
Cells 2019 Sep 16;8(9):1091.doi: 10.3390/cells8091091

FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal
Schelch K, Wagner C, Hager S, Pirker C, Siess K, Lang E, Lin R, Kirschner MB, Mohr T, Brcic L, Marian B, Holzmann K, Grasl-Kraupp B, Krupitza G, Laszlo V, Klikovits T, Dome B, Hegedus B, Garay T, Reid G, van Zandwijk N, Klepetko W, Berger W, Grusch M, Hoda MA.
Carcinogenesis. 2018 Apr 5;39(4):534-545

FGF5 is expressed in melanoma and enhances malignancy in vitro and in vivo
Ghassemi S, Vejdovszky K, Sahin E, Ratzinger L, Schelch K, Mohr T, Peter-Vörösmarty B, Brankovic J, Lackner A, Leopoldi A, Meindl D, Pirker C, Hegedus B, Marian B, Holzmann K, Grasl-Kraupp B, Heffeter P, Berger W, Grusch M.
Oncotarget. 2017 Sep 23;8(50):87750-87762

The Optogenetic Promise for Oncology: Episode I
Ingles-Prieto A, Reichhart E, Schelch K, Janovjak H, Grusch M.
Molecular and Cellular Oncology (2014), DOI:10.4161/23723548.2014.964045

Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy
Schelch K, Hoda MA, Klikovits T, Münzker J, Ghanim B, Wagner C, Garay T, Laszlo V, Setinek U, Dome B, Filipits M, Pirker C, Heffeter P, Selzer E, Tovari J, Torok S, Kenessey I, Holzmann K, Grasl-Kraupp B, Marian B, Klepetko W, Berger W, Hegedus B, Grusch M.
Am J Respir Crit Care Med. 2014 Oct 1;190(7):763-72

Spatio-temporally precise activation of engineered receptor tyrosine kinases by light
Grusch M, Schelch K, Riedler R, Reichhart E, Differ C, Berger W, Inglés-Prieto Á, Janovjak H.
EMBO J. 2014 Aug 1;33(15):1713-26

All Publications


Presentation Wolfgang Mikulits, Michael Grusch